Atrion Reports Fourth Quarter And Full Year 2023 Results
- None.
- Operating income decreased in Q4 2023 compared to the same period in 2022.
- Net income declined significantly in both Q4 2023 and full year 2023 compared to the previous year.
- The company's operating margin dropped to 13.3% in 2023, a significant decrease from the industry-leading 20% in previous years.
- Global supply chain disruptions led to under-absorption of labor costs as sales slowed down.
Insights
From a financial standpoint, Atrion Corporation's Q4 and full-year 2023 results indicate a mixed performance, with a slight uptick in quarterly sales but a significant decline in annual revenue and net income. This divergence suggests that while the company may be seeing some recovery, the overall yearly performance was heavily impacted by external factors, specifically global supply chain issues. The reduction in operating margin to 13.3% from a consistent 20% benchmark is a critical point for investors, as it reflects a lower profitability that could affect the company's valuation.
Investors should note the under-absorption of labor costs due to slowed sales, which indicates fixed costs are not being effectively leveraged against revenue, pressuring profit margins. The mention of electronic component shortages impacting the MPS 3 cardiac surgery consoles is significant as it highlights the company's vulnerability to supply chain disruptions and how these can directly affect product availability and sales.
Furthermore, the change in customer ordering patterns, with OEM customers reducing orders after stockpiling in the previous year, demonstrates the challenges in forecasting demand in volatile markets. This could lead to more conservative future revenue projections and potential adjustments in inventory management strategies.
The supply chain dynamics described by Atrion's CEO underscore the broader challenges faced by many companies in the healthcare equipment sector. The electronic component shortages that affected Atrion's ability to meet customer demand for its cardiac surgery consoles are indicative of the ripple effects of global supply chain disruptions. This situation highlights the importance of supply chain resilience and the need for robust risk management strategies.
For Atrion, the shift in OEM customer behavior from over-ordering to 'right-sizing' inventories reflects a normalization process as supply chain pressures ease. However, it also suggests that Atrion may need to reassess its supply chain strategy to better adapt to changing market conditions and customer behaviors. The company's future success will likely depend on its ability to forecast demand more accurately and manage inventory levels to prevent overproduction and under-absorption scenarios.
Investors and stakeholders should be aware of the potential long-term implications, such as the need for Atrion to invest in supply chain optimization, which could include diversifying suppliers, increasing inventory buffers, or implementing more flexible manufacturing systems.
The healthcare equipment industry is highly competitive and Atrion's performance must be contextualized within this landscape. The 2% sales increase in Q4 suggests a potential stabilization in a segment of their market, but the significant year-over-year decline in net income and operating margin presents a concern for market competitiveness. It's important to analyze customer trends and market demand to understand the longer-term outlook for Atrion's product lines, especially the fluid delivery and cardiovascular products mentioned.
Given the company's historical performance and industry-leading operating margins, the current decline may affect investor perceptions and the company's market position. The competitive analysis should focus on how Atrion's challenges with supply chain and production levels compare to its peers. If competitors have managed these issues more effectively, Atrion could be at a disadvantage in terms of market share and pricing power.
Understanding the broader market response to global supply chain disruptions and inventory adjustments will be critical for predicting Atrion's recovery trajectory. Stakeholders should monitor industry trends, such as technological advancements and regulatory changes, that could influence product demand and the company's ability to adapt to market needs.
ALLEN, Texas, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the fourth quarter ended December 31, 2023 and the full year 2023.
For the fourth quarter of 2023 compared to the fourth quarter of 2022, revenues were
Commenting on 2023 quarterly results compared to the comparable 2022 periods, David Battat, President and CEO, stated, “Looking at the 2023 and comparable 2022 quarters sequentially, we saw a continuous easing of revenue declines throughout the year, culminating with a
For the full year 2023 compared to the prior year, revenues were
Mr. Battat added, “Our 2023 results do not reflect our efforts, initiatives, or new ideas. Against a challenging backdrop, our teams continued the hard work to ensure our future growth. Our MPS 3 console production is now at record levels to meet strong demand. Although 2023 OEM sales were deferred, we did not lose any major customers – in fact, every multi-year supply agreement that expired in 2023 was renewed for additional multi-year terms. More importantly, in 2023 our new product pipeline grew faster than at any point in our history. The OEM side of our business saw the launch of several new partnerships. We estimate that these partnerships alone will add tens of millions of dollars in new revenue by 2030—and this is in addition to organic growth of existing and new products already in our pipeline. Our factory expansion completed in 2023 provides the specialized infrastructure that was required to compete for these projects.”
Mr. Battat concluded, “For 2024, we expect a high single digit increase in revenue, returning us to, or near, the record level reached in 2022 as we introduce new technologies to the market and current customers achieve rightsized inventories. Increases in operating income will be challenging in the first half of the year as we fill orders from our own inventory and, as a result, under-absorb overhead. Operating income should improve in the second half of the year as our inventory depletion will require a resumption of idled production lines. We ended 2023 debt free and with cash and short- and long-term investments totaling
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding revenue from new partnerships, organic growth of existing and new products in the Company’s pipeline, and 2024 revenues and operating income levels. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that COVID-19 leads to further material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to COVID-19; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that COVID-19 further disrupts local economies and causes economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.
Contact: Cindy Ferguson
Vice President and Chief Financial Officer
(972) 390-9800
| ATRION CORPORATION UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues | $ | 43,584 | $ | 42,855 | $ | 169,326 | $ | 183,506 | |||||||
| Cost of goods sold | 27,267 | 24,681 | 106,938 | 107,602 | |||||||||||
| Gross profit | 16,317 | 18,174 | 62,388 | 75,904 | |||||||||||
| Operating expenses | 9,653 | 9,369 | 39,809 | 36,217 | |||||||||||
| Operating income | 6,664 | 8,805 | 22,579 | 39,687 | |||||||||||
| Interest and dividend income | 119 | 349 | 806 | 988 | |||||||||||
| Other investment income (loss) | 505 | (366 | ) | (900 | ) | (150 | ) | ||||||||
| Other income | -- | -- | 39 | 92 | |||||||||||
| Interest expense | (25 | ) | -- | (149 | ) | -- | |||||||||
| Income before income taxes | 7,263 | 8,788 | 22,375 | 40,617 | |||||||||||
| Income tax provision | (839 | ) | (466 | ) | (2,964 | ) | (5,609 | ) | |||||||
| Net income | $ | 6,424 | $ | 8,322 | $ | 19,411 | $ | 35,008 | |||||||
| Income per basic share | $ | 3.65 | $ | 4.70 | $ | 11.02 | $ | 19.59 | |||||||
| Weighted average basic shares outstanding | 1,760 | 1,770 | 1,761 | 1,787 | |||||||||||
| Income per diluted share | $ | 3.65 | $ | 4.70 | $ | 11.02 | $ | 19.56 | |||||||
| Weighted average diluted shares outstanding | 1,761 | 1,771 | 1,761 | 1,790 | |||||||||||
| ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands) | |||||
| December 31, | December 31, | ||||
| ASSETS | 2023 | 2022 | |||
| Current assets: | |||||
| Cash and cash equivalents | $ | 3,565 | $ | 4,731 | |
| Short-term investments | 2,691 | 21,152 | |||
| Total cash and short-term investments | 6,256 | 25,883 | |||
| Accounts receivable | 23,029 | 23,951 | |||
| Inventories | 82,307 | 65,793 | |||
| Prepaid expenses and other | 3,173 | 3,770 | |||
| Total current assets | 114,765 | 119,397 | |||
| Long-term investments | 8,165 | 8,669 | |||
| Property, plant and equipment, net | 125,347 | 123,754 | |||
| Other assets | 12,548 | 12,892 | |||
| $ | 260,825 | $ | 264,712 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
| Current liabilities | 12,621 | 18,098 | |||
| Line of credit | -- | -- | |||
| Other non-current liabilities | 5,315 | 7,073 | |||
| Stockholders’ equity | 242,889 | 239,541 | |||
| $ | 260,825 | $ | 264,712 | ||
FAQ
What were Atrion Corporation's (ATRI) revenues for Q4 2023?
How did Atrion Corporation's (ATRI) operating income change in Q4 2023 compared to Q4 2022?
What was Atrion Corporation's (ATRI) net income for the full year 2023?
What factor contributed to the decline in Atrion Corporation's (ATRI) operating margin in 2023?
